Monoclonal Antibodies (mAbs) targeting the CD47 protein are currently the most advanced and widely studied class of agents in the CD47 Targeting Therapeutics domain. Their established history in oncology, high specificity for the target protein, and potential for potent macrophage activation make them the preferred modality for initial drug development.
These antibodies function primarily by...
The domain of therapeutics focused on CD47 targeting is rapidly emerging as a foundational pillar of next-generation cancer immunotherapy. CD47, a protein universally expressed on healthy cells, acts as a "don't eat me" signal when it binds to the SIRP-alpha receptor on immune cells like macrophages. Cancer cells frequently overexpress CD47 to exploit this pathway, allowing them to evade the...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
คลิกดาวน์โหลด
thai
English
French
Spanish
Portuguese
Italiano
Romaian
china